Dec 22, 2025 • GuruFocus
BULLISH
KYMR: B. Riley Securities Raises Price Target for Kymera Therape
B. Riley Securities has reiterated its "Buy" rating on Kymera Therapeutics (KYMR) and significantly increased its price target to $117.00, a 46.25% jump from the previous $80.00. This follows a trend of several prominent firms raising their price targets for KYMR, reflecting a positive sentiment. However, GuruFocus estimates the GF Value for KYMR in one year at $18.45, suggesting a potential downside of 78.25% from its current price.
Dec 22, 2025 • marketscreener.com
BULLISH
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating
B. Riley has increased its price target for Kymera Therapeutics (NASDAQ: KYMR) shares to $117 from $80, while maintaining a "Buy" rating. This adjustment comes as Kymera Therapeutics, a biopharmaceutical company, shows promising developments in its clinical programs, particularly in immunology-inflammation and oncology. The company's recent announcements, including positive Phase 1b trial results for KT-621 and FDA Fast Track designation, have likely contributed to the analyst's upgraded outlook.
Dec 22, 2025 • Simply Wall Street
BULLISH
Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?
Kymera Therapeutics (KYMR) recently received Fast Track designation from the FDA for its oral STAT6 degrader, KT-621, following positive Phase 1b results in atopic dermatitis. This development, coupled with a US$602 million equity offering, is expected to reshape the investment narrative by sharpening focus on KT-621 as a key clinical catalyst. However, investors must also consider the increased dilution from the offering and the company's high cash burn.
Dec 20, 2025 • Simply Wall Street
BULLISH
Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod
Kymera Therapeutics (KYMR) has received positive Phase 1b data for its KT-621 oral STAT6 degrader and an FDA Fast Track designation, leading to significant share price gains. Despite this momentum, the company remains loss-making and investors face a key question regarding its valuation, with the stock currently considered 26.3% undervalued based on a popular narrative valuing it at $114. This valuation relies on aggressive revenue scaling and margin expansion, but also carries risks due to high R&D spend and reliance on KT-621's success.
Dec 20, 2025 • MarketBeat
NEUTRAL
Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR
Squarepoint Ops LLC significantly reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 32.3% in Q2, selling 15,865 shares. Despite substantial insider selling amounting to $41.4 million over 90 days, Wall Street analysts maintain a largely bullish outlook with a consensus "Buy" rating and an average target price of $114.45. Kymera Therapeutics, a clinical-stage biopharmaceutical company, reported a Q3 earnings miss but continues to attract institutional interest from other firms increasing their positions.
Dec 18, 2025 • The Globe and Mail
BULLISH
Kymera Therapeutics (KYMR) Gets a Buy from Wells Fargo
Wells Fargo analyst Derek Archila maintained a Buy rating on Kymera Therapeutics (KYMR) with a $116.00 price target. This re-affirms positive sentiment despite a recent Hold rating reissue by another firm and a reported GAAP net loss of $82.18 million. Corporate insider sentiment is neutral, though a director recently sold a significant number of shares.